BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study in collaboration with The University of Texas MD Anderson Cancer Center, ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
To gain better insight into what's happening in the brain, researchers examine the molecules produced by brain cells, ...
Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone formation in the spine, leading to severe neurological symptoms due to spinal ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, is recognizing Colorectal Cancer Awareness Month by highlighting the ...
Peking University, August 18, 2025: A research team led by Professor Wang Yangming from the Institute of Molecular Medicine, College of Future Technology, and the Beijing Advanced Center of RNA ...
Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of ...
Evaluation of 68Ga-FAPI PET/CT and 18F-FDG PET/CT for the primary staging of non-small cell lung cancer (NSCLC). Application of an epigenomic-based classifier to identify cancer signal of origin on ...
Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results